Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 12:19:1863-1876.
doi: 10.2147/OPTH.S524956. eCollection 2025.

Two-Year Post-Market Surveillance of iStent inject ® W Combined with Phacoemulsification in Japanese Open-Angle Glaucoma Eyes

Masaru Inatani  1 , Ichiro Kohama  2 , Alice Chu  3
Affiliations

Two-Year Post-Market Surveillance of iStent inject ® W Combined with Phacoemulsification in Japanese Open-Angle Glaucoma Eyes

Masaru Inatani et al. Clin Ophthalmol. .

Abstract

Purpose: To evaluate 2-year safety and effectiveness of iStent inject ® W implantation with phacoemulsification in adult Japanese open-angle glaucoma (OAG) patients.

Design: Multicenter, prospective, post-market surveillance.

Methods: Eyes were evaluated preoperatively and at Day 1, Week 1, and Months (M) 1, 3, 6, 12, and 24. Primary outcome was M24 cumulative probability of success defined as no additional glaucoma surgery and intraocular pressure (IOP) < preoperative value and number of glaucoma medications ≤ preoperative value or IOP ≤ preoperative value and number of glaucoma medications < preoperative value. Other endpoints included cumulative probability of achieving American Academy of Ophthalmology Glaucoma (AAO) success criteria for minimally invasive glaucoma surgery with phacoemulsification, and changes in mean IOP, number of glaucoma medications, and medication costs over time. Subanalysis was based on OAG subtype [primary open-angle glaucoma (POAG), normal tension glaucoma (NTG), and exfoliative glaucoma (XFG)]. Adverse events were recorded.

Results: Cumulative probability of success at M24 was 91.7%, 98.8%, 88.9%, and 85.0% for cohort (N = 214), NTG, XFG, and POAG, respectively. The AAO M24 success was 80.7%. Statistically significant reductions in mean IOP and number of medications were observed through M24 in cohort and OAG subtypes. At M24, the estimated reductions in mean (standard error) IOP and number of medications were 2.0 (0.5) mmHg and 1.9 (0.4), respectively, in the cohort. Adverse events were minimal. At M24, the average monthly glaucoma medication costs decreased by 49.7%.

Conclusion: Japanese OAG eyes treated with iStent inject W combined with phacoemulsification experienced reduced IOP and medication burden with minimal adverse events and high success rates over postoperative 2 years.

Keywords: Japan; minimally invasive glaucoma surgery; trabecular micro-bypass.

PubMed Disclaimer

Conflict of interest statement

Masaru Inatani receives lecture fees and honorarium from Glaukos Japan. Ichiro Kohama is an employee of Glaukos Japan. Alice Chu is an employee of Glaukos Singapore and shareholder of Glaukos Corporation.

Figures

Figure 1
Figure 1
Post-market surveillance success in the cohort (A) and by OAG subtype (B).
Figure 2
Figure 2
AAO MIGS with phacoemulsification success in the cohort (A) and by OAG subtype (B).
Figure 3
Figure 3
Predicted proportion of eyes in IOP ranges for the cohort (A), POAG (B), NTG (C), and XFG (D) at preoperative time point and postoperative month 24.
Figure 4
Figure 4
Predicted proportion of eyes in number of glaucoma medication ranges for the cohort (A), POAG (B), NTG (C), and XFG (D) at preoperative time point and postoperative month 24.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111(9):1641–1648. doi: 10.1016/j.ophtha.2004.03.029 - DOI - PubMed
    1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. doi: 10.1016/j.ophtha.2014.05.013 - DOI - PubMed
    1. Fujiwara K, Yasuda M, Hata J, et al. Prevalence of glaucoma and its systemic risk factors in a general Japanese population: the Hisayama Study. Transl Vis Sci Technol. 2022;11(11):11. doi: 10.1167/tvst.11.11.11 - DOI - PMC - PubMed
    1. Bedrood S, Berdahl J, Sheybani A, Singh IP. Alternatives to topical glaucoma medication for glaucoma management. Clin Ophthalmol. 2023;17:3899–3913. doi: 10.2147/OPTH.S439457 - DOI - PMC - PubMed
    1. Radcliffe NM, Shah M, Samuelson TW. Challenging the “topical medications-first” approach to glaucoma: a treatment paradigm in evolution. Ophthalmol Ther. 2023;12(6):2823–2839. doi: 10.1007/s40123-023-00831-9 - DOI - PMC - PubMed

LinkOut - more resources